A new generation of cancer genome diagnostics for routine clinical use: Overcoming the roadblocks to personalized cancer medicine

Annals of Oncology

Volumn 26, Issue 9, 2015, Pages 1830-1837

  Heuckmann, J M ^a   Thomas, Roman K ^b  

^a NEO New Oncology GmbH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cancer; Cancer genome diagnostics; FFPE; Personalized medicine

Indexed keywords

FORMALDEHYDE;

AMPLICON; CANCER GENOME DIAGNOSTICS; CANCER THERAPY; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMORBIDITY; COPY NUMBER VARIATION; DIAGNOSTIC PROCEDURE; DNA LIBRARY; EXON; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC PROCEDURES; GENETIC SCREENING; GENOTYPE; GERMLINE MUTATION; HUMAN; LUNG CANCER; MEASUREMENT ACCURACY; MOLECULAR DIAGNOSTICS; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SOMATIC COPY NUMBER ALTERATION; TUMOR BIOPSY; TUMOR GENE; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PROCEDURES;

GENE AMPLIFICATION; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PRECISION MEDICINE; SEQUENCE ANALYSIS, DNA;

EID: 84941636993     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv184     Document Type: Review

References (58)

1. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
2. Lynch T, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
3. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
4. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
5. Shaw A, Engelman J. ALK in lung cancer: past, present, and future. J Clin Oncol 2013; 31: 1105-1111.
6. Kwak E, Bang Y, Camidge R et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
7. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
8. Mok T, Wu Y, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
9. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
10. Buettner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013; 31: 1858-1865.
11. Gautschi O, Zander T, Keller FA et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013; 8: e43-e44.
12. Rothschild S, Gautschi O. Crizotinib in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2013: 14:473-480.
13. Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-381.
14. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963-1971.
15. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
16. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
17. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
18. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
19. Wu Y-M, SU F, Kalyana-Sundaram S et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; 3: 636-647.
20. O'Shaughnessy J, Osborne C, Pippen J et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
21. Romond E, Perez E, Bryant J, Suman V. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
22. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013; 3: 27-34.
23. Awad MM, Katayama R, McTigue M et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013; 368: 2395-2401.
24. Choi Y, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
25. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
26. Shaw AT, Kim DW, Mehra R et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189-1197.
27. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
28. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
29. Gajiwala KS, Wu JC, Christensen J et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009; 106: 1542-1547.
30. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31: 3987-3996.
31. Walter AO, Sjin RT, Haringsma HJ et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013; 3: 1404-1415.
32. Cross DE, Ashton SE, Ghiorghiu S et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-1061.
33. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 11: 473-481.
34. NGM. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.
35. Vasan N, Yelensky R, Wang K et al. Therapeutically targetable alterations in primary and metastatic breast a targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice 0-7. 2014; 19: 453-458.
36. Kerick M, Isau M, Timmermann B et al. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 2011; 4: 68.
37. Hadd AG, Houghton J, Choudhary A et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 2013; 15: 234-247.
38. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-696.
39. Thomas RK, Nickerson E, Simons JF et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006; 12: 852-855.
40. Querings S, Altmüller J, Ansén S et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011; 6: e19601.
41. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
42. Tuononen K, Mäki-Nevala S, Kaur Sarhadi V et al. Comparison of targeted nextgeneration sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of nonsmall cell lung carcinoma-superiority of NGS. Genes Chromosom Cancer 2013; 52: 503-511.
43. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006; 354: 526-528.
44. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-1031.
45. Malchers F, Dietlein F, Schöttle J et al. Cell-autonomous and non-cellautonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov 2014; 4: 246-257.
46. Fernandez-Cuesta L, Plenker D, Osada H et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 2014; 4: 415-422.
47. Peifer M, Fernández-Cuesta L, Sos ML et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44: 1104-1110.
48. Gnirke A, Melnikov A, Maguire J et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009; 27: 182-189.
49. Hagemann IS, Cottrell CE, Lockwood CM. Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy. Cancer Genet 2013; 206: 420-431.
50. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012; 18: 382-384.
51. Abel HJ, Duncavage EJ. Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches. Cancer Genet 2013; 206: 432-440.
52. Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
53. Gargis AS, Kalman L, Berry MW et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 2012; 30: 1033-1036.
54. Newman AM, Bratman SV, To J et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20: 548-554.
55. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
56. Imielinski M, Berger AH, Hammerman PS et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-1120.
57. Berger MF, Hodis E, Heffernan TP et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485: 502-506.
58. Dienstmann R, Dong F, Borger D et al. Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol Oncol 2014; 8: 859-873.